Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b

키워드

참고문헌 (42)

1. Syed GH, "Hepatitis C virus hijacks host lipid metabolism", Trends Endocrinol Metab, 21, pp.33~40 (2010)[DOI]
2. "Gastroenterology", 2003, 1695~1704, 10.1053[DOI]
3. Felmlee DJ, "Hepatitis C virus, cholesterol and lipoproteins: impact for the viral life cycle and pathogenesis of liver disease", Viruses, 5, pp.1292~1324 (2013)[DOI]
4. Andre P, "Characterization of low- and very-low-density hepatitis C virus RNA-containing particles", J Virol, 76, pp.6919~6928 (2002)[DOI]
5. Diaz O, "Preferential association of hepatitis C virus with apolipoprotein B48-containing lipoproteins", J Gen Virol, 87, pp.2983~2991 (2006)[DOI]
6. Bassendine MF, "Lipids and HCV", Semin Immunopathol, 35, pp.87~100 (2013)[DOI]
7. Aizawa Y, "Chronic hepatitis C virus infection and lipoprotein metabolism", World J Gastroenterol, 21, pp.10299~10313 (2015)[DOI]
8. Waris G, "Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress", J Virol, 81, pp.8122~8130 (2007)[DOI]
9. Dharancy S, "Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection", Gastroenterology, 128, pp.334~342 (2005)[DOI]
10. Yamaguchi A, "Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver", Dig Dis Sci, 50, pp.1361~1371 (2005)[DOI]
11. Perlemuter G, "Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis", FASEB J, 16, pp.185~194 (2002)[DOI]
12. Fukuhara T, "Roles of lipoproteins and apolipoproteins in particle formation of hepatitis C virus", Trends Microbiol, 23, pp.618~629 (2015)[DOI]
13. Rowell J, "Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis", Hepatol Int, 6, pp.475~481 (2012)[DOI]
14. Seki N, "Assessment of the features of serum apolipoprotein profiles in chronic HCV infection: difference between HCV genotypes 1b and 2", Hepatol Int, 8, pp.550~559 (2014)[DOI]
15. Moriya K, "Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan", Hepatol Res, 25, pp.371~376 (2003)[DOI]
16. Hayashi N, "Simeprevir with peginterferon", ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial, 2014, pp.61, 219~227
17. Hayashi N, "Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C", J Viral Hepat, 19, pp.e134~e142 (2012)[DOI]
18. Poordad F, "Boceprevir for untreated chronic HCV genotype 1 infection", N Engl J Med, 364, pp.1195~1206 (2011)[DOI]
19. van der Meer AJ, "Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis", JAMA, 308, pp.2584~2593 (2012)[DOI]
20. Veldt BJ, "Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis", Ann Intern Med, 147, pp.677~684 (2007)[DOI]
21. Morgan TR, "Outcome of sustained virological responders with histologically advanced chronic hepatitis C", Hepatology, 52, pp.833~844 (2010)[DOI]
22. Corey KE, "Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up", Hepatology, 50, pp.1030~1037 (2009)[DOI]
23. Andrade RJ, "Effects of interferon-beta on plasma lipid and lipoprotein composition and post-heparin lipase activities in patients with chronic hepatitis C", Aliment Pharmacol Ther, 14, pp.929~935 (2000)[DOI]
24. Shinohara E, "Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C", Hepatology, 25, pp.1502~1506 (1997)[DOI]
25. Schectman G, "The effect of interferon on the metabolism of LDLs", Arterioscler Thromb, 12, pp.1053~1062 (1992)[DOI]
26. Kumada H, "Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection", Hepatology, 59, pp.2083~2091 (2014)[DOI]
27. Meissner EG, "Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients", Hepatology, 61, pp.790~801 (2015)[DOI]
28. Hashimoto S, "Rapid increase in serum low-density lipoprotein cholesterol concentration during hepatitis C interferon-free treatment", PLoS One, 11, pp.e0163644~ (2016)[DOI]
29. Younossi ZM, "Ledipasvir", sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels, 2015, pp.22, 977~982
30. Feingold KR, "Role of cytokines in inducing hyperlipidemia", Diabetes, 41(Suppl 2), pp.97~101 (1992)[DOI]
31. 정희재, "The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients", Clinical and Molecular Hepatology, 20(1), pp.38~46 (2014), 대한간학회[DOI]
32. Lee TH, "MicroRNA-122 associates with serum apolipoprotein B but not liver fibrosis markers in CHC genotype 1 infection", J Med Virol, 87, pp.1722~1726 (2015)[DOI]
33. Bassendine MF, "HCV and the hepatic lipid pathway as a potential treatment target", J Hepatol, 55, pp.1428~1440 (2011)[DOI]
34. Backus LI, "Predictors of response of US veterans to treatment for the hepatitis C virus", Hepatology, 46, pp.37~47 (2007)
35. Lange CM, "Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-alpha-2a and ribavirin", Eur J Gastroenterol Hepatol, 22, pp.1303~1307 (2010)[DOI]
36. Berg T, "Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study", Liver Int, 35, pp.448~454 (2015)[DOI]
37. Gopal K, "Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment", Hepatology, 44, pp.335~340 (2006)[DOI]
38. Sheridan DA, "Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin", Aliment Pharmacol Ther, 29, pp.1282~1290 (2009)[DOI]
39. Harrison SA, "Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy", Hepatology, 52, pp.864~874 (2010)
40. Li JH, "Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection", Hepatology, 51, pp.1904~1911 (2010)[DOI]
41. Meissner EG, "IFNL4-deltaG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin", J Infect Dis, 209, pp.1700~1704 (2014)[DOI]
42. Zeuzem S, "Faldaprevir and deleobuvir for HCV genotype 1 infection", N Engl J Med, 369, pp.630~639 (2013)[DOI]

관련 논문AI추천